<DOC>
	<DOC>NCT02633033</DOC>
	<brief_summary>This observational study aims to characterize the patient population and describe multiple sclerosis exacerbation recovery, treatment patterns and safety outcomes in patients with multiple sclerosis experiencing exacerbations treated with H.P. Acthar® Gel (Acthar Gel) in standard practice in the United States.</brief_summary>
	<brief_title>Observational Registry of H.P. Acthar® Gel for Multiple Sclerosis Relapse</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Adrenocorticotropic Hormone</mesh_term>
	<criteria>1. Male or Female ≥ 18 years of age. 2. Patient has a clinically definite relapsing form of Multiple Sclerosis according to McDonald Criteria (2010 revision). 3. Patient with an acute MS exacerbation as determined by their treating clinician. 4. Patient planning to initiate Acthar Gel for the treatment of an acute MS exacerbation. 5. Patient capable of providing informed consent. 1. Patients with a diagnosis of Progressive MS. 2. Patients that require concomitant corticosteroid therapy. 3. Patients receiving experimental drug therapy. 4. Patients with a history of scleroderma, systemic fungal infections, ocular herpes simplex, or cancer within prior 5 years. 5. Patients who had recent surgery or have a history of or the presence of a peptic ulcer within 6 months prior to study entry, congestive heart failure, or sensitivity to proteins of porcine origin. 6. If female, pregnant or breastfeeding; or, if of childbearing age, an unwillingness to use appropriate birth control.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>